Wednesday, July 8, 2026

pharma · Asthma · Osteoarthritis · AMRX

Amneal Pharma Europe

Amneal Pharma Europe is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker AMRX. Primary therapeutic focus areas include Asthma, Osteoarthritis, Schizophrenia, Open-angle Glaucoma, Pa

400 Crossing Boulevard, Bridgewater, New Jersey 08807, US HQ
2002 Founded
7,179 Employees
Public company Type
AMRX · NYSE Ticker
Company details
Status
Public
HQ
400 Crossing Boulevard, Bridgewater, New Jersey 08807, US
Founded
2002
Employees
7,179
Programs
15
Drugs
210
Patents
32
Clinical program

KSHN001126 150mg

Phase 1 · small molecule · Healthy Postmenopausal Women

KSHN001126 150mg for Healthy Postmenopausal Women is a Phase 1 program (small_molecule) at Amneal Pharma Europe Ltd with 1 ClinicalTrials.gov record(s).

← All Amneal Pharma Europe Ltd projects Phase 1 small molecule completed

Internal code CE-24-02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Amneal Pharma Europe Ltd
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Postmenopausal Women
Status
completed
Trials
1

Clinical trials